Molecular Therapy Review Time

The official ScienceDirect insights page is useful, but it tells only part of the story.

It tells you:

• the journal positions itself as a leading venue for gene transfer, vector design, stem cell manipulation, and therapeutic platforms
• the current official public timeline is 136 days from submission to acceptance
• the journal supports both subscription and open-access routes
• the journal is indexed broadly and carries strong Scopus and JCR metrics

It does not tell you:

• a public median desk-rejection time
• a public median first-decision time
• how much faster transferred or unusually strong cases might move

That is why the safest planning model is still "multi-month flagship review cycle."

That is the practical author model. Even if one reviewed case moves fast, the journal itself is telling you not to build a schedule around that.

The journal sometimes feels fast because authors see a smooth accepted case, or because a well-positioned therapy paper can move cleanly through section editors and reviewers.

That can happen when:

• the therapeutic platform consequence is obvious early
• the delivery or engineering logic is already mature
• the translational claim is proportionate to the data
• the manuscript clearly belongs in flagship Molecular Therapy rather than a narrower family journal

But the public official number still tells you that this is not the norm.

The slower cases are usually not administrative accidents. They are papers that force the journal to decide how much field-level therapeutic consequence is really there.

Common sources of delay are:

• disease-specific efficacy stories with weaker platform consequence
• missing durability, safety, or manufacturability context
• revisions that must sharpen the therapy logic rather than just the writing
• papers that might actually belong in a narrower Molecular Therapy family lane

That is why the elapsed time often reflects journal identity more than reviewer mood.

That profile matches the timing posture. A journal like this is deciding field ownership, not just technical correctness.

This matters because timing disappointment is often a journal-ownership mistake.

For year-over-year impact factor data, see the molecular therapy impact factor page.

Directionally, the open citation signal is effectively flat, down from 9.43 in 2023 to 9.40 in 2024. That stability matters because it suggests the journal is not in a rapid transition phase. The editorial identity is mature and stable, which usually means authors should expect consistent, not experimental, handling standards.

Review-time data hides the key distinction at Molecular Therapy:

• one smooth accepted case does not define the journal
• official timeline data matter more than anecdotal fast cases
• the real timing variable is whether the manuscript changes the therapeutic field, not just whether it works in one indication

That is why the safer planning model is the official one.

In our pre-submission review work with Molecular Therapy manuscripts, the timing mistake we see most often is authors treating the journal like a reward for any good gene-therapy or cell-therapy paper.

It is not.

The papers that move best here usually have:

• a therapeutic advance that matters beyond one disease
• a platform or delivery logic that is load-bearing
• translational claims that are proportionate to the evidence
• fewer signs that the paper is actually a narrower family-journal fit

Those traits improve timing because they reduce the chance of a long editorial debate about what kind of paper this really is.

In our pre-submission review work on Molecular Therapy-targeted manuscripts, three patterns most consistently predict slow review at Molecular Therapy (Cell Press). Of manuscripts we screened in 2025 targeting Molecular Therapy and peer venues, the patterns below are the same ones our reviewers flag in real time. The named editorial-culture quirk: Molecular Therapy reviewers expect both mechanistic depth and explicit clinical-translation pathway for gene/cell-therapy applications.

Scope-fit ambiguity in the abstract. Molecular Therapy editors move fastest on manuscripts whose contribution is obviously aligned with the journal's editorial scope (gene therapy and cell therapy research with mechanistic depth and explicit clinical-translation pathway). The named failure pattern: mechanism-only gene/cell-therapy papers without clinical-translation pathway extend revision rounds. Check whether your abstract reads to Molecular Therapy's scope →

Methods package incomplete for the journal's reviewer pool. Molecular Therapy reviewers expect specific methodological detail. Clinical observational studies without mechanistic underpinning extend reviewer consultation. Check if your methods package is reviewer-complete →

Reference-list and clean-citation failure mode. Editorial team at Molecular Therapy (Cell Press) screens reference lists for retracted-paper inclusion. Check whether your reference list is clean against Crossref + Retraction Watch →

Editorial detail (for desk-screen calibration). Verify the current Editor-in-Chief and handling-editor list on the journal's editorial-team page before quoting any name in a submission cover letter. Submission portal: https://www.editorialmanager.com/molther/. Manuscript constraints: 200-word abstract limit and 50,000-character (~7,500-word) main-text cap (Molecular Therapy enforces during desk-screen). We reviewed each of these constraints against current journal author guidelines (accessed 2026-05-08); evidence basis for the patterns above includes both publicly documented author-guidelines and our internal anonymized submission corpus.

Manusights submission-corpus signal for Molecular Therapy (Cell Press). Of the manuscripts our team screened before submission to Molecular Therapy and peer venues in 2025, the editorial-culture mismatch most consistent across the cohort is Molecular Therapy reviewers expect both mechanistic depth and explicit clinical-translation pathway for gene/cell-therapy applications. In our analysis of anonymized Molecular Therapy-targeted submissions, the documented review timeline shows a bimodal distribution between manuscripts that clear Molecular Therapy's scope-fit threshold within the first week and those that get extended editorial-board consultation. Top-line triage is handled by the journal's editorial team; verify the current handling editor on the journal's editorial-team page before quoting any name in a cover letter.

For Molecular Therapy, speed matters less than therapeutic field consequence and platform fit.

That is why the better next reads are:

• Molecular Therapy submission guide
• Molecular Therapy impact factor
• How to avoid desk rejection at Molecular Therapy
• How to choose the right journal for your paper

A Molecular Therapy fit check is usually more useful than relying on the fastest anecdote you can find.

Molecular Therapy review time should be planned as a several-month flagship-journal process. The safest public anchor is the official 136-day submission-to-acceptance number. Authors should not build their expectations around the much faster but tiny community sample.

The Manusights Molecular Therapy readiness scan. This guide tells you what Molecular Therapy (Cell Press)'s editors look for in the first 1-2 weeks of triage. The review tells you whether YOUR paper passes that check before you submit. We have reviewed manuscripts targeting Molecular Therapy (Cell Press) and peer venues; the named patterns below are the same ones the journal's handling editors and outside reviewers flag at the desk-screen and first-review stages. documented review timeline of approximately 7-10 days for desk-screen. 60-day money-back guarantee. We do not train AI on your manuscript and delete it within 24 hours.